Incyte Corp. (INCY)

73.64
0.66 0.90
NASDAQ : Health Technology
Prev Close 72.98
Open 73.38
Day Low/High 72.78 / 74.30
52 Wk Low/High 60.23 / 140.11
Volume 1.30M
Avg Volume 2.52M
Exchange NASDAQ
Shares Outstanding 211.97M
Market Cap 15.27B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Lifshitz & Miller LLP Announces Investigation Of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc., And Spectrum Brands Holdings, Inc.

Lifshitz & Miller LLP Announces Investigation Of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc., And Spectrum Brands Holdings, Inc.

NEW YORK, June 5, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. (ARMO) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of ARMO to Eli Lilly, whereby shareholders will receive $50.

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets For The Treatment Of Adults With Moderately-to-Severely Active Rheumatoid Arthritis

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets For The Treatment Of Adults With Moderately-to-Severely Active Rheumatoid Arthritis

The approval of OLUMIANT is based on the Phase 3 clinical trial program that demonstrated efficacy for difficult to treat patients1

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 2:40 pm (PDT) / 5:40 pm (EDT) in...

Sirius XM Radio, Teva Pharmaceuticals: 'Mad Money' Lightning Round

Sirius XM Radio, Teva Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer weighs in on Sirius XM Radio, Teva Pharmaceuticals, iQIYI, Blue Apron, Shopify, Incyte, E*Trade Financial and more.

Big Turnaround Stories: Cramer's 'Mad Money' Recap (Wednesday 5/23/18)

Big Turnaround Stories: Cramer's 'Mad Money' Recap (Wednesday 5/23/18)

Jim Cramer tells investors to keep their eyes open for companies making changes -- that's what's being rewarded.

Incyte Reports 2018 First-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Reports 2018 First-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2018 first-quarter financial results, highlighting strong growth in total product-related revenue and providing a status update on the Company's development portfolio.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 8:40 am PDT in Las Vegas.

Incyte Highlights Abstracts Accepted For Presentation At The 2018 ASCO Annual Meeting

Incyte Highlights Abstracts Accepted For Presentation At The 2018 ASCO Annual Meeting

Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts from its research and development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois from June 1-5, 2018.

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Lilly's chairman and CEO David Ricks said in an earnings call that he was confident in the risk-benefit profile for both proposed doses of the new drug.

These Stocks Were Hit Hardest in Friday's Selloff

These Stocks Were Hit Hardest in Friday's Selloff

China's response to U.S. tariffs has markets tanking Friday, eating into the gains from a mostly positive week.

Incyte And Merck Provide Update On Phase 3 Study Of Epacadostat In Combination With KEYTRUDA® (pembrolizumab) In Patients With Unresectable Or Metastatic Melanoma

Incyte And Merck Provide Update On Phase 3 Study Of Epacadostat In Combination With KEYTRUDA® (pembrolizumab) In Patients With Unresectable Or Metastatic Melanoma

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that an external Data Monitoring Committee (eDMC) review of the pivotal Phase 3 ECHO-301/KEYNOTE-252...

Incyte Targeted Therapy And Immuno-Oncology Portfolio To Be Featured In 15 Abstracts At The AACR Annual Meeting 2018

Incyte Targeted Therapy And Immuno-Oncology Portfolio To Be Featured In 15 Abstracts At The AACR Annual Meeting 2018

Incyte Corporation (Nasdaq:INCY) announces that 15 abstracts from its research and development portfolio will be presented at the upcoming 2018 American Association for Cancer Research (AACR) annual meeting in Chicago,...

The New #21 Most Shorted Nasdaq 100 Component: Incyte

The New #21 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 02/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

(Photo: Business Wire)

(Photo: Business Wire)

Incyte Corporation (Nasdaq:INCY) joins the National Organization for Rare Disorders (NORD), the European Organization for Rare Diseases (EURORDIS), and other rare disease health organizations and advocates in recognizing...

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 38 th Annual Health Care Conference on Tuesday,...

Incyte Reports 2017 Fourth-Quarter And Year-End Financial Results, Provides 2018 Financial Guidance And Updates On Key Clinical Programs

Incyte Reports 2017 Fourth-Quarter And Year-End Financial Results, Provides 2018 Financial Guidance And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2017 fourth-quarter and year-end financial results, highlighting both strong growth in total revenue and the significant progress being made across the product portfolio.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 2018 RBC Capital Markets Global Healthcare Conference on Wednesday, February 21, 2018 at 11:00 am (ET) in New York.

Incyte Updates Conference Call Time To Report Fourth Quarter And Year-End Financial Results

Incyte Updates Conference Call Time To Report Fourth Quarter And Year-End Financial Results

Incyte Corporation (Nasdaq:INCY) announced today an update to the conference call and webcast time for its fourth quarter and year end 2017 financial results to 8:00 a.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year end 2017 financial results conference call and webcast for 10:00 a.

Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer By TRC Capital Corporation

Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer By TRC Capital Corporation

Incyte Corporation (Nasdaq:INCY) today announced that it received notice of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to 1,500,000 shares of Incyte's common stock at a price of $88.

Incyte Moves Up In Analyst Rankings, Passing Fidelity National Information Services

Incyte Moves Up In Analyst Rankings, Passing Fidelity National Information Services

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Incyte Corporation has taken over the #79 spot from Fidelity National Information Services Inc , according to ETF Channel. Below is a chart of Incyte Corporation versus Fidelity National Information Services Inc plotting their respective rank within the S&P 500 over time (INCY plotted in blue; FIS plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Incyte And Syros Announce Global Target Discovery And Validation Collaboration Focused On Myeloproliferative Neoplasms

Incyte And Syros Announce Global Target Discovery And Validation Collaboration Focused On Myeloproliferative Neoplasms

Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced today that the companies have entered into a target discovery, research collaboration and option agreement.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 36 th Annual J.

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Verisk Analytics

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Verisk Analytics

The most recent short interest data has been released for the 11/30/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

TheStreet Quant Rating: D (Sell)